secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001708599-26-000005
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's
--------------------------------------------------------------------------------

- FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.
- Phase 1b registrational study to start; site and regulatory activities in Australia underway.
- FDA alignment on 505(b)(2) NDA pathway provides clear development path for SER-252.
- CEO Steve Ledger calls milestone a major step toward addressing significant unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000005/0001708599-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000005/ser-20260127.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer